Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yvonne Kirchhein"'
Autor:
Alexandra Albus, Maike Gold, Jan-Philipp Bach, Monika Burg-Roderfeld, Marit Jördens, Yvonne Kirchhein, Yannick Kronimus, David Mengel, Inga Zerr, Richard Dodel
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0202954 (2018)
BACKGROUND:Abnormal aggregation of proteins induces neuronal cell loss in neurodegenerative disorders such as Alzheimer's Disease, Creutzfeldt-Jakob Disease and Parkinson's Disease. Specific stimuli initialize conformational changes in physiological
Externí odkaz:
https://doaj.org/article/61c947684c314131800b9a744734f09b
Autor:
Philip Home, Karin Wernicke-Panten, Satish K. Garg, Karl-Michael Derwahl, Monika Ziemen, Suzanne Pierre, Yvonne Kirchhein
Publikováno v:
Diabetes Technology & Therapeutics
Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (Humalog®; Ly-Lis). Two randomized, controlled, open-label, parallel-group, phase 3 studies were conducted to compare the efficacy and safety of SAR-Lis and Ly-Lis, both i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a19651a3ab90d31ee41f9d6b6a5ac33
https://doi.org/10.1089/dia.2017.0373
https://doi.org/10.1089/dia.2017.0373
Autor:
Suzanne Pierre, Karin Wernicke-Panten, Satish K. Garg, Maria Rojeski, Krystyna Jedynasty, Yvonne Kirchhein
Publikováno v:
Diabetes Technology & Therapeutics. 19:516-526
SAR342434 is a biosimilar follow-on of insulin lispro-HumalogSORELLA-1 was a randomized, open-label phase 3 study (NCT02273180). Patients completing the 6-month main study continued on SAR-Lis or Ly-Lis, as randomized, for a 6-month safety extension.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b4b4bcea8a0d5caa742bda74c574962
https://doi.org/10.1089/dia.2017.0117
https://doi.org/10.1089/dia.2017.0117
Autor:
Martin R. Farlow, Junyi Liu, Timothy Zhu, Hongjun Peng, Gang Zhao, James A. Mastrianni, Yansheng Du, Huiying Gu, Yvonne Kirchhein, Eileen Du, Richard Dodel
Publikováno v:
Molecular neurobiology. 56(4)
Our previous studies showed that intravenous immunoglobulin (IVIG) contained anti-Aβ autoantibodies that might be able to treat Alzheimer’s disease (AD). Recently, we identified and characterized naturally occurring autoantibodies against PrP from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce478ab0a126cce73ccebcaaaf5b2408
https://pubmed.ncbi.nlm.nih.gov/30027340
https://pubmed.ncbi.nlm.nih.gov/30027340